Compare SUVEN LIFE with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES SANOFI INDIA SUVEN LIFESCIENCES/
SANOFI INDIA
 
P/E (TTM) x 19.7 33.6 58.6% View Chart
P/BV x 4.0 5.9 67.7% View Chart
Dividend Yield % 0.5 1.5 35.7%  

Financials

 SUVEN LIFESCIENCES   SANOFI INDIA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
SANOFI INDIA
Dec-18
SUVEN LIFESCIENCES/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3386,840 4.9%   
Low Rs1694,630 3.7%   
Sales per share (Unadj.) Rs52.11,203.1 4.3%  
Earnings per share (Unadj.) Rs6.8165.3 4.1%  
Cash flow per share (Unadj.) Rs8.6209.9 4.1%  
Dividends per share (Unadj.) Rs1.5084.00 1.8%  
Dividend yield (eoy) %0.61.5 40.4%  
Book value per share (Unadj.) Rs65.3963.6 6.8%  
Shares outstanding (eoy) m127.2823.03 552.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.94.8 102.0%   
Avg P/E ratio x37.134.7 107.0%  
P/CF ratio (eoy) x29.627.3 108.3%  
Price / Book Value ratio x3.96.0 65.3%  
Dividend payout %22.050.8 43.2%   
Avg Mkt Cap Rs m32,272132,078 24.4%   
No. of employees `0001.13.3 32.8%   
Total wages/salary Rs m6614,068 16.3%   
Avg. sales/employee Rs Th6,132.28,393.8 73.1%   
Avg. wages/employee Rs Th611.11,232.4 49.6%   
Avg. net profit/employee Rs Th803.51,153.0 69.7%   
INCOME DATA
Net Sales Rs m6,63527,708 23.9%  
Other income Rs m242897 27.0%   
Total revenues Rs m6,87728,605 24.0%   
Gross profit Rs m1,6046,235 25.7%  
Depreciation Rs m2211,027 21.6%   
Interest Rs m387 538.6%   
Profit before tax Rs m1,5876,098 26.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7182,292 31.3%   
Profit after tax Rs m8693,806 22.8%  
Gross profit margin %24.222.5 107.4%  
Effective tax rate %45.237.6 120.3%   
Net profit margin %13.113.7 95.4%  
BALANCE SHEET DATA
Current assets Rs m6,23215,922 39.1%   
Current liabilities Rs m1,4906,235 23.9%   
Net working cap to sales %71.535.0 204.4%  
Current ratio x4.22.6 163.8%  
Inventory Days Days8664 135.8%  
Debtors Days Days8321 395.9%  
Net fixed assets Rs m4,0437,539 53.6%   
Share capital Rs m127230 55.3%   
"Free" reserves Rs m8,18321,962 37.3%   
Net worth Rs m8,31022,192 37.4%   
Long term debt Rs m180-   
Total assets Rs m10,38929,839 34.8%  
Interest coverage x43.1872.1 4.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.9 68.8%   
Return on assets %8.712.8 68.3%  
Return on equity %10.517.2 61.0%  
Return on capital %19.527.5 70.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,6227,587 74.1%   
Fx outflow Rs m1,7997,145 25.2%   
Net fx Rs m3,822442 864.8%   
CASH FLOW
From Operations Rs m3563,739 9.5%  
From Investments Rs m-279-731 38.1%  
From Financial Activity Rs m-225-1,972 11.4%  
Net Cashflow Rs m-1481,036 -14.3%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 0.0 14.4 -  
FIIs % 0.0 14.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 10.5 347.6%  
Shareholders   37,287 15,184 245.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   FULFORD INDIA  AUROBINDO PHARMA  IPCA LABS  WOCKHARDT  SUN PHARMA  

Compare SUVEN LIFESCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Falling Gold Prices, Global Stock Market Drivers, and Top Cues in Focus Today(Pre-Open)

On Thursday, Indian share markets witnessed negative trading activity throughout the day and ended deep in the red.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Sep 19, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS